[go: up one dir, main page]

PE20131403A1 - Anticuerpos anti-ox40 y metodos de uso de los mismos - Google Patents

Anticuerpos anti-ox40 y metodos de uso de los mismos

Info

Publication number
PE20131403A1
PE20131403A1 PE2013000332A PE2013000332A PE20131403A1 PE 20131403 A1 PE20131403 A1 PE 20131403A1 PE 2013000332 A PE2013000332 A PE 2013000332A PE 2013000332 A PE2013000332 A PE 2013000332A PE 20131403 A1 PE20131403 A1 PE 20131403A1
Authority
PE
Peru
Prior art keywords
includes seq
seq
variable region
antibodies
methods
Prior art date
Application number
PE2013000332A
Other languages
English (en)
Inventor
Young-Jun Liu
Kui Shin Voo
Laura Bover
Naoya Tsurushita
J Yun Tso
Shankar Kumar
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of PE20131403A1 publication Critical patent/PE20131403A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

REFERIDO A UN ANTICUERPO AISLADO EL CUAL ENLAZA OX40, CARACTERIZADO POR QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA CDR1 QUE CONTIENE LA SECUENCIA DE AMINOACIDOS SEC ID NO: 1,13; CDR2 COMPRENDE SEC ID NO: 2,14; CDR3 COMPRENDE SEC ID NO: 3,15 Y B) LA REGION VARIABLE DE CADENA LIGERA CDR1 COMPRENDE SEC ID NO: 7,19; CDR2 COMPRENDE SEC ID NO 8,20; CDR3 COMPRENDE SEC ID NO 9,21. DICHO ANTICUERPO ES UTIL PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES AUTOIMUNES.
PE2013000332A 2010-08-23 2011-08-23 Anticuerpos anti-ox40 y metodos de uso de los mismos PE20131403A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37599910P 2010-08-23 2010-08-23
US38082710P 2010-09-08 2010-09-08

Publications (1)

Publication Number Publication Date
PE20131403A1 true PE20131403A1 (es) 2014-01-10

Family

ID=45724011

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017002714A PE20180042A1 (es) 2010-08-23 2011-08-23 Anticuerpos anti-ox40 y metodos de uso de los mismos
PE2013000332A PE20131403A1 (es) 2010-08-23 2011-08-23 Anticuerpos anti-ox40 y metodos de uso de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2017002714A PE20180042A1 (es) 2010-08-23 2011-08-23 Anticuerpos anti-ox40 y metodos de uso de los mismos

Country Status (35)

Country Link
US (6) US9006399B2 (es)
EP (2) EP2609118B1 (es)
JP (2) JP5984810B2 (es)
KR (2) KR101704865B1 (es)
CN (2) CN106554417B (es)
AP (1) AP2013006771A0 (es)
AU (1) AU2011293558B2 (es)
BR (2) BR112013004266A8 (es)
CA (1) CA2809089C (es)
CL (3) CL2013000545A1 (es)
CO (1) CO6680693A2 (es)
CR (1) CR20130126A (es)
CY (1) CY1118928T1 (es)
DK (1) DK2609118T3 (es)
DO (1) DOP2013000045A (es)
EA (2) EA031849B1 (es)
ES (2) ES2630328T3 (es)
HR (1) HRP20170568T1 (es)
HU (1) HUE031371T2 (es)
IL (2) IL224886A (es)
LT (1) LT2609118T (es)
ME (1) ME02678B (es)
MX (1) MX339964B (es)
MY (1) MY171312A (es)
NZ (3) NZ629913A (es)
PE (2) PE20180042A1 (es)
PH (1) PH12013500354B1 (es)
PL (1) PL2609118T3 (es)
PT (1) PT2609118T (es)
RS (1) RS55952B1 (es)
SG (1) SG187945A1 (es)
SI (1) SI2609118T1 (es)
SM (1) SMT201700185T1 (es)
WO (1) WO2012027328A2 (es)
ZA (1) ZA201301442B (es)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028231A1 (en) * 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
SI2609118T1 (sl) * 2010-08-23 2017-05-31 The Board Of Regents, The University Of Texas System Protitelesa proti ox40 in postopki uporabe istih
EA036047B1 (ru) * 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US20150322119A1 (en) 2012-12-03 2015-11-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
BR112015020787B1 (pt) 2013-03-06 2022-12-06 Astrazeneca Ab Compostos 4-(substituído-anilino)-6-o-(substituídopiperizina-carbonil)quinazolínicos, seus sais, composição farmacêutica, uso e combinação
AU2014238546C1 (en) * 2013-03-18 2019-01-17 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
US11273204B2 (en) 2013-08-08 2022-03-15 Cytune Pharma IL-15 and IL-15RAPLHA sushi domain based immunocytokines
CN106029889A (zh) * 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN114081946A (zh) * 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
EP3322443A1 (en) * 2015-07-13 2018-05-23 Yeda Research and Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
AU2015241038A1 (en) * 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
ES2774381T3 (es) 2014-04-03 2020-07-20 Univ Res Inst Inc Augusta Métodos para mejorar la eficacia de la respuesta inmune dirigida a tumores
JP6920194B2 (ja) 2014-08-19 2021-08-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｔｉｇｉｔ抗体
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
MX2017005751A (es) 2014-11-03 2018-04-10 Genentech Inc Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
CN106796235B (zh) 2014-11-03 2021-01-29 豪夫迈·罗氏有限公司 用于检测t细胞免疫子集的测定法及其使用方法
BR112017008628A2 (pt) 2014-11-06 2018-01-30 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
CA2967368A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
PT3265123T (pt) 2015-03-03 2023-02-01 Kymab Ltd Anticorpos, usos e métodos
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
SG11201708804WA (en) * 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017021913A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
US20180222989A1 (en) * 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017021910A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
TW201716084A (zh) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017030823A2 (en) * 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
MX2018003820A (es) 2015-10-02 2018-12-10 F Hoffmann ­La Roche Ag Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
CN114380908B (zh) * 2015-10-15 2023-03-17 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
GB201520903D0 (en) * 2015-11-26 2016-01-13 Qbd Qs Ip Ltd Purification method
CA3006934A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
WO2017096281A1 (en) * 2015-12-02 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
HK1250032A1 (zh) 2015-12-03 2018-11-23 Glaxosmithkline Intellectual Property Development Limited 作为sting调节剂的环状嘌呤二核苷酸
CA3006963A1 (en) * 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
MX387354B (es) 2016-04-07 2025-03-18 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas.
CN109563081A (zh) 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
PE20190106A1 (es) 2016-05-05 2019-01-15 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homologo zeste 2
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018025221A1 (en) 2016-08-04 2018-02-08 Glaxosmithkline Intellectual Property Development Limited Anti-icos and anti-pd-1 antibody combination therapy
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CA3033661A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US20190343803A1 (en) 2016-12-01 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Combination therapy
KR20190090823A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 요법
BR122020025629B1 (pt) 2016-12-15 2022-05-31 Abbvie Biotherapeutics Inc Anticorpo anti-ox40, composição farmacêutica que compreende o mesmo e método in vitro para a produção do dito anticorpo
MX2019007144A (es) 2016-12-19 2019-10-07 Glenmark Pharmaceuticals Sa Nuevos agonistas de tnfr y sus usos.
AU2018205234B2 (en) 2017-01-06 2024-09-19 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
EP3582855A1 (en) 2017-02-15 2019-12-25 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
JP2020522516A (ja) 2017-06-05 2020-07-30 アイオバンス バイオセラピューティクス，インコーポレイテッド 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法
WO2018225035A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
CA3066038A1 (en) * 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
US11760791B2 (en) 2017-09-13 2023-09-19 Radimmune Therapeutics, Inc. Melanin antibodies and uses thereof
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
SG11202004457XA (en) 2017-11-17 2020-06-29 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
CN111344019B (zh) 2017-12-29 2024-03-15 圆祥生技股份有限公司 调节免疫检查点作为癌症治疗的单特异性与双特异性蛋白质
WO2019136456A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN110092832B (zh) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
BR112020021660A2 (pt) 2018-04-27 2021-02-02 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação
AU2019264712A1 (en) * 2018-05-11 2021-01-07 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against OX40, method for preparing same, and use thereof
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
BR112020023746A2 (pt) * 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
CA3113541A1 (en) * 2018-09-26 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
KR20210099573A (ko) 2018-11-05 2021-08-12 이오반스 바이오테라퓨틱스, 인크. 개선된 종양 반응성 t-세포의 선택
WO2020096989A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
US20220017629A1 (en) * 2018-11-20 2022-01-20 Shanghai Pharmaexplorer Co., Ltd. Ox40 antibody, preparation method thereof and use thereof
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
BR112021014911A2 (pt) 2019-02-01 2021-11-23 Glaxosmithkline Ip Dev Ltd Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer
MX2021011608A (es) 2019-03-29 2021-12-10 Myst Therapeutics Llc Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
BR112021025476A2 (pt) 2019-06-26 2022-10-11 Glaxosmithkline Ip Dev Ltd Proteínas de ligação à il1rap
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4011389A4 (en) * 2019-08-09 2024-09-04 Riken COMBINED USE OF ARTIFICIAL AUXILIARY VECTOR CELLS AND IMMUNE STIMULANT
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
PH12022550671A1 (en) 2019-09-27 2023-05-29 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc Method of producing tumor-reactive t cell composition using modulatory agents
JP7749561B2 (ja) 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
MX2022007712A (es) * 2019-12-17 2022-09-26 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
CA3164751A1 (en) 2019-12-18 2021-06-24 Benjamin Joseph MORROW Compounds
CN113135994A (zh) * 2020-01-19 2021-07-20 迈威(上海)生物科技股份有限公司 一种激活型抗ox40抗体、生产方法及应用
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
BR112022016490A2 (pt) 2020-02-27 2022-10-11 Myst Therapeutics Llc Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
US20230172987A1 (en) 2020-05-04 2023-06-08 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CN112442121A (zh) * 2020-08-20 2021-03-05 山东兴瑞生物科技有限公司 Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
CA3202473A1 (en) 2020-12-17 2022-06-23 Friedrich Graf Finckenstein Treatment of cancers with tumor infiltrating lymphocytes
EP4262811A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
DK4267105T3 (da) 2020-12-28 2025-05-19 Bristol Myers Squibb Co Antistofsammensætninger og fremgangsmåder til anvendelse deraf
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CN112957475B (zh) * 2021-02-04 2022-07-22 李文峰 一种预防和或治疗肿瘤的组合物及应用
JP2024509529A (ja) 2021-03-02 2024-03-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｄｎｍｔ１阻害剤としての置換ピリジン
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202308669A (zh) 2021-04-19 2023-03-01 美商艾歐凡斯生物治療公司 嵌合共刺激性受體、趨化激素受體及彼等於細胞免疫治療之用途
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
WO2023049862A1 (en) 2021-09-24 2023-03-30 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
IL314346A (en) 2022-03-15 2024-09-01 Compugen Ltd Antibodies antagonistic to IL-18BP and their use in monotherapy and combination therapy in cancer treatment
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compounds and methods of using them
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
AU2023342646A1 (en) 2022-09-15 2025-02-20 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024235862A1 (en) 2023-05-12 2024-11-21 Genmab A/S Antibodies capable of binding to ox40, variants thereof and uses thereof
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025021131A1 (en) * 2023-07-25 2025-01-30 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Methods of treating alopecia areata and atopic dermatitis
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
DK1060247T3 (da) 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US20020004041A1 (en) * 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1366196A4 (en) 2001-02-14 2004-07-07 Baylor College Medicine RNA AMPLIFICATION METHODS AND COMPOSITIONS
AU2002226390B2 (en) 2001-12-22 2007-11-15 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
DE60106469T2 (de) 2001-12-22 2005-10-13 4-Antbody AG Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
WO2003106498A2 (en) 2002-06-13 2003-12-24 Crucell Holland, B.V. Agonistic binding molecules to the human ox40 receptor
EP1578459A3 (en) 2002-10-25 2005-11-23 University of Connecticut Health Center Apparatus and method for immunotherapy of a cancer through controlled cell lysis
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
JP2007501775A (ja) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
PT1674111E (pt) * 2004-07-09 2010-12-15 Chugai Pharmaceutical Co Ltd Anticorpo anti-glipicano 3
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
CN101111522A (zh) 2004-12-02 2008-01-23 杜门蒂斯有限公司 由于和功能域抗体缀合而具有提高的血清半衰期的plad功能域肽
EP1833848A2 (en) 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
US7786266B2 (en) 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AT502823B1 (de) 2005-11-29 2007-06-15 Seitz Alexander Dr Polynukleotid-amplifikation
ZA200804868B (en) 2005-12-16 2009-10-28 Genentech Inc Anti-OX40L antibodies and methods using same
US20110008368A1 (en) 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
US20080286286A1 (en) 2006-01-13 2008-11-20 Board Of Regents, The University Of Texas System Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
RU2009135824A (ru) 2007-02-27 2011-04-10 Дженентек, Инк. (Us) Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2851374B1 (en) 2007-12-14 2017-05-03 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
JP5782385B2 (ja) 2009-02-17 2015-09-24 ユーシービー ファーマ ソシエテ アノニム ヒトｏｘ４０に対する特異性を有する抗体分子
SG10201501784YA (en) 2009-12-07 2015-05-28 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
SI2609118T1 (sl) * 2010-08-23 2017-05-31 The Board Of Regents, The University Of Texas System Protitelesa proti ox40 in postopki uporabe istih
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
EA036047B1 (ru) 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
JP6224739B2 (ja) 2013-03-15 2017-11-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗ｌａｇ−３結合タンパク質
AU2015241038A1 (en) * 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
SG11201708804WA (en) * 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
SI3303396T1 (sl) * 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
EP3582855A1 (en) * 2017-02-15 2019-12-25 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer

Also Published As

Publication number Publication date
US9695246B2 (en) 2017-07-04
IL224886A (en) 2017-11-30
US20170267773A1 (en) 2017-09-21
US20160068604A1 (en) 2016-03-10
JP2017018110A (ja) 2017-01-26
US20130280275A1 (en) 2013-10-24
SG187945A1 (en) 2013-03-28
DOP2013000045A (es) 2014-02-28
IL250691B (en) 2019-05-30
MX2013002172A (es) 2013-06-28
EP2609118B1 (en) 2017-01-18
ZA201301442B (en) 2014-07-30
KR20140093600A (ko) 2014-07-28
WO2012027328A2 (en) 2012-03-01
CN103221427A (zh) 2013-07-24
BR112013004266A2 (pt) 2016-08-02
US10196450B2 (en) 2019-02-05
IL250691A0 (en) 2017-04-30
WO2012027328A3 (en) 2012-05-31
PH12013500354A1 (en) 2013-03-25
SI2609118T1 (sl) 2017-05-31
CN106554417B (zh) 2020-11-06
CA2809089C (en) 2018-12-18
CN103221427B (zh) 2016-08-24
HK1213272A1 (en) 2016-06-30
JP5984810B2 (ja) 2016-09-06
NZ608033A (en) 2014-09-26
MX339964B (es) 2016-06-17
ME02678B (me) 2017-06-20
CL2016003052A1 (es) 2017-08-04
CL2013000545A1 (es) 2014-09-26
AP2013006771A0 (en) 2013-03-31
EA201500204A1 (ru) 2015-11-30
PE20180042A1 (es) 2018-01-09
NZ716369A (en) 2017-05-26
SMT201700185T1 (it) 2017-05-08
EP2609118A4 (en) 2014-03-19
US9527917B2 (en) 2016-12-27
PH12013500354B1 (en) 2018-10-19
PT2609118T (pt) 2017-03-22
EP2933268A1 (en) 2015-10-21
EA201390278A1 (ru) 2013-08-30
US9163085B2 (en) 2015-10-20
JP2013538057A (ja) 2013-10-10
KR20160149322A (ko) 2016-12-27
CA2809089A1 (en) 2012-03-01
DK2609118T3 (en) 2017-04-03
MY171312A (en) 2019-10-08
CN106554417A (zh) 2017-04-05
AU2011293558A1 (en) 2013-03-21
CY1118928T1 (el) 2018-01-10
US9006399B2 (en) 2015-04-14
ES2630328T3 (es) 2017-08-21
US20190100596A1 (en) 2019-04-04
NZ629913A (en) 2016-01-29
JP6317788B2 (ja) 2018-04-25
PL2609118T3 (pl) 2017-07-31
KR101704865B1 (ko) 2017-02-09
HRP20170568T1 (hr) 2017-06-30
US10851173B2 (en) 2020-12-01
EA029793B1 (ru) 2018-05-31
KR101719118B1 (ko) 2017-03-22
US20140308276A1 (en) 2014-10-16
LT2609118T (lt) 2017-04-25
EA031849B1 (ru) 2019-03-29
CO6680693A2 (es) 2013-05-31
HUE031371T2 (en) 2017-07-28
EP2609118A2 (en) 2013-07-03
RS55952B1 (sr) 2017-09-29
ES2649155T3 (es) 2018-01-10
CL2015002526A1 (es) 2016-06-10
US20150315281A1 (en) 2015-11-05
BR112014003982A2 (pt) 2017-05-09
AU2011293558B2 (en) 2014-07-31
BR112013004266A8 (pt) 2018-01-02
EP2933268B1 (en) 2017-07-12
CR20130126A (es) 2013-06-28

Similar Documents

Publication Publication Date Title
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20140247A1 (es) Anticuerpos anti-cd38
PE20141017A1 (es) Anticuerpos del cea
PE20131209A1 (es) Anticuerpos anti-fap
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PE20190737A1 (es) Anticuerpos anti-cd27
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
MX338758B (es) Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.
PE20141568A1 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20130159A1 (es) Anticuerpos anti-cd40
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
AR084315A1 (es) Anticuerpos anti-notch1
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20110797A1 (es) Anticuerpos anti mn
PE20160553A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
NZ712765A (en) Antibodies that bind csf1r

Legal Events

Date Code Title Description
FG Grant, registration